Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

160
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
160
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

182
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
182
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

696
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
696
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

290
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
290
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

145
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
145
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

62
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
62

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Psychedelics action and schizophrenia.

Pharmacological reports : PR·2024
Same author

Limbic System Response to Psilocybin and Ketamine Administration in Rats: A Neurochemical and Behavioral Study.

International journal of molecular sciences·2024
Same author

TC-G 1008 facilitates epileptogenesis by acting selectively at the GPR39 receptor but non-selectively activates CREB in the hippocampus of pentylenetetrazole-kindled mice.

Cellular and molecular life sciences : CMLS·2023
Same author

Epigenetic Targets in Schizophrenia Development and Therapy.

Brain sciences·2023
Same author

Gene Expression and Epigenetic Regulation in the Prefrontal Cortex of Schizophrenia.

Genes·2023
Same author

Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior.

International journal of molecular sciences·2022

Related Experiment Video

Updated: Jul 12, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K

Psychedelics action and schizophrenia.

Marzena Maćkowiak1

  • 1Laboratory of Pharmacology and Brain Biostructure, Pharmacology Department, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland. mackow@if-pan.krakow.pl.

Pharmacological Reports : PR
|October 30, 2023
PubMed
Summary
This summary is machine-generated.

Psychedelics, acting via serotonin 5-HT2A receptors, show therapeutic potential for neuropsychiatric disorders. However, their psychosis-like effects necessitate careful dosing or non-hallucinogenic analogs for schizophrenia treatment.

Keywords:
5-HT2A receptorHallucinogensMental disorderTherapy

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.5K
Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.0K

Related Experiment Videos

Last Updated: Jul 12, 2025

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.5K
Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.0K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Psychedelics activate serotonin 5-HT2A receptors, impacting behavior and showing promise for depression and PTSD.
  • Schizophrenia shares neurobiological pathways with psychedelics, including impaired serotonergic and glutamatergic systems.
  • Schizophrenia is characterized by synaptic loss, contrasting with psychedelics' neuroplastic effects.

Purpose of the Study:

  • To explore the potential therapeutic applications of psychedelics in schizophrenia treatment.
  • To investigate the shared neurobiological mechanisms between psychedelics and schizophrenia.
  • To address the challenges and potential strategies for using psychedelics in schizophrenia therapy.

Main Methods:

  • Review of existing findings on psychedelic actions and schizophrenia symptoms.
  • Analysis of neurobiological similarities, including neurotransmitter systems and neuroplasticity.
  • Discussion of therapeutic strategies, including dosing and non-hallucinogenic analogs.

Main Results:

  • Psychedelics and schizophrenia exhibit overlapping neurobiological features, particularly involving serotonin and glutamate pathways.
  • Psychedelics promote neuroplasticity (synaptogenesis, neurogenesis), potentially counteracting synaptic loss in schizophrenia.
  • The psychotogenic effects of psychedelics pose a challenge for schizophrenia treatment, suggesting subpsychedelic or microdosing approaches.

Conclusions:

  • Psychedelics offer potential for schizophrenia therapy due to their neuroplastic effects, despite shared psychosis-related pathways.
  • Further research is crucial to establish safe and effective dosing regimens, potentially involving non-hallucinogenic analogs.
  • Exploratory preclinical and clinical studies are needed to validate the efficacy of 5-HT2A agonists in managing schizophrenia.